COMPANY PROFILE · /bioage-labs
B
BioAge Labs
AI-driven therapeutics company researching molecular pathways that contribute to aging and healthspan. Uses systems biology and machine learning trained on clinical and molecular data from thousands of patients to develop novel small-molecule therapeutics for aging-related diseases, oncology, and CNS disorders.
Fresh · 5d ago
Latest valuation
$1B+ (post-IPO, 2025)
Annual Recurring Revenue
—
Headcount
~150-200 (estimated)
Funding total
$408M+ (Series D + IPO proceeds)
OVERVIEW
Series D ($170M, 2025) led by Sofinnova. Followed by NASDAQ IPO + private placement ($238.3M). Two lead candidates in clinical development: APJ agonists and NLRP3 inhibitors (BGE-102). Phase 1 data anticipated end of 2025.
Status
active
Tier
master-list
Profitability
Cash runway through 2029
Pricing
enterprise
FUNDING HISTORY · 0
No funding rounds on file.
PRODUCTS · 0
No products catalogued yet. Press Refresh above to ask the research agent.
TEAM · 0 key people
No people linked.
SOURCES · 0 cited
No citations stored yet. Run the research agent to attach per-claim sources.